Side Effects of niraparib: A Synthesis of Findings from 10 Studies

  1. Home
  2. Side Effects of niraparib
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of niraparib: A Synthesis of Findings from 10 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of niraparib: A Synthesis of Findings from 10 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Research Findings

Niraparib is a PARP inhibitor that has been shown to be effective for the treatment of recurrent ovarian cancer and metastatic castration-resistant prostate cancer (mCRPC). 7 , 6 , 5 , 10 It has been approved by the FDA as a maintenance therapy for patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. 7 Niraparib is also being studied in combination with other drugs for the treatment of mCRPC. 10

Reason for Side Effects

Niraparib is a PARP inhibitor, which targets DNA repair enzymes. This mechanism can lead to side effects by affecting healthy cells as well. 8 2 1

Common Side Effects

Hematologic Side Effects

Niraparib has been reported to cause hematologic side effects such as thrombocytopenia, anemia, and neutropenia. 7 , 2 , 1 These side effects are thought to be caused by niraparib affecting cells in the bone marrow.

Gastrointestinal Side Effects

Niraparib has been reported to cause gastrointestinal side effects such as nausea, vomiting, constipation, and loss of appetite. 7 , 2 , 1 These side effects are thought to be caused by niraparib affecting cells in the gastrointestinal tract.

Other Side Effects

Niraparib has also been reported to cause other side effects such as fatigue, headache, insomnia, rash, and hypertension. 7 , 2 , 1 A case of life-threatening niraparib-induced pneumonitis has also been reported. 3

Countermeasures for Side Effects

Hematologic Side Effects

Treatment for hematologic side effects includes blood transfusions and growth factors.

Gastrointestinal Side Effects

Treatment for gastrointestinal side effects includes antiemetics and laxatives.

Comparison between Studies

Commonalities

Many studies have shown that niraparib is an effective treatment. Niraparib has also been shown to have common side effects, including hematologic and gastrointestinal side effects.

Differences

There may be differences in the types and frequencies of side effects reported in different studies.

Points to Note Regarding Application to Real Life

Niraparib is an effective drug for the treatment of cancer, but it has been found to have side effects. Therefore, when using niraparib, it is important to be aware of these side effects and to seek medical attention if you experience any concerning symptoms.

Limitations of Current Research

There is still not enough research on the long-term effects and side effects of niraparib.

Future Research Directions

Further research is needed on the long-term effects and side effects of niraparib, combination therapies to enhance efficacy, and new indications.

Conclusion

Niraparib is an effective drug for the treatment of cancers such as ovarian cancer and prostate cancer, but it has been found to have side effects. It is important to be aware of these side effects and to seek medical attention if you experience any concerning symptoms.

Literature analysis of 10 papers
Positive Content
9
Neutral Content
1
Negative Content
0
Article Type
0
1
1
4
9
3.

First-Line PARP Inhibitors-Emerging Side Effects Require Caution: A Case of PARPi-Induced Pneumonitis.

Author: McLarenAlistair, CartwrightDouglas, RossEwen, RoxburghPatricia

Improved PFS
Maintenance Treatment
Bone Marrow Suppression
Hypertension
Pneumonitis

Niraparib, a drug used to treat ovarian cancer, has been shown to improve progression-free survival. However, this case report highlights a potential life-threatening side effect of niraparib, pneumonitis, which was not reported in previous clinical trials.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

4.

Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale.

Author: SandhuDaranjit, AntolinAlbert A, CoxAnthony R, JonesAlan M

Anemia
Diarrhea
Fatigue
Hepatotoxicity
Hypertension
Hypothyroidism
Myelosuppression
Nausea
Neutropenia
Thrombocytopenia
Vomiting

The polypharmacology of PARP inhibitors, despite their similar mode of action, influences their adverse drug reaction (ADR) profile. This suggests that the choice of PARP inhibitor should consider the specific ADR profile of each drug.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.

Author: RuscitoIlary, BellatiFilippo, Ray-CoquardIsabelle, MirzaMansoor Raza, du BoisAndreas, GasparriMaria Luisa, CostanziFlavia, De MarcoMaria Paola, NutiMarianna, CasertaDonatella, PignataSandro, DorigoOliver, SehouliJalid, BraicuElena Ioana

ovarian cancer treatment

PARP inhibitors are a new class of targeted agents that are effective and safe for the treatment of recurrent and primary advanced ovarian cancer.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

6.

Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.

Author: MullenMary M, KurokiLindsay M, ThakerPremal H

Anti-angiogenesis therapy
EOC treatment
PARP inhibitor maintenance
Platinum-free interval
Bevacizumab side effects
Cediranib side effects
EOC recurrence
Trebananib side effects

This review discusses pivotal trials establishing platinum-based combination chemotherapy as the standard of care for epithelial ovarian cancer and addresses the utility of increasing a patient's platinum-free interval.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

7.

FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.

Author: IsonGwynn, HowieLynn J, Amiri-KordestaniLaleh, ZhangLijun, TangShenghui, SridharaRajeshwari, PierreVadryn, CharlabRosane, RamamoorthyAnuradha, SongPengfei, LiFang, YuJingyu, ManhengWimolnut, PalmbyTodd R, GhoshSoma, HorneHisani N, LeeEunice Y, PhilipReena, DaveKaushalkumar, ChenXiao Hong, KellySharon L, JanoriaKumar G, BanerjeeAnamitro, EradiriOkponanabofa, DininJeannette, GoldbergKirsten B, PierceWilliam F, IbrahimAmna, KluetzPaul G, BlumenthalGideon M, BeaverJulia A, PazdurRichard

Ovarian cancer treatment
Progression-free survival
Acute myeloid leukemia
Myelodysplastic syndrome

Niraparib, a PARP inhibitor, has been approved for maintenance therapy in patients with recurrent ovarian cancer. It improves progression-free survival regardless of BRCA mutation status.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

9.

Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics.

Author: PapachristosApostolos, PatelJai, VasileiouMaria, PatrinosGeorge P

Dose optimization

This review discusses the challenges of dose optimization in oncology, particularly with targeted therapies. The role of pharmacological tools like pharmacogenomics and pharmacodynamics in supporting dose optimization is explored.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

[Combination therapy with poly(adenosine diphosphate-ribose) polymerase (PARPi) and androgen receptor signaling pathway (ARPi) inhibitors for metastatic castration-resistant prostate cancer].

Author: GrimmMarc-Oliver, FollerSusan, LeuchtKatharina

mCRPC treatment
Side effects

PARPi plus ARPi combination therapies have been approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients with BRCA mutations. The article discusses the pivotal clinical trials, potential side effects, and management strategies for these combination therapies.

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : German

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.